Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 1, 2012, Pages 42-55

  Walker, Kyle M ^a   Pope, Janet ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Algorithm; Guidelines; Management; Scleroderma; Systemic sclerosis; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; ILOPROST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ARTHRITIS; ARTICLE; BLOOD PRESSURE MONITORING; CONSENSUS DEVELOPMENT; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG TOLERABILITY; FINGER ULCER; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; INTESTINAL DYSMOTILITY; KIDNEY DISEASE; LUNG FIBROSIS; MALABSORPTION; MEDICAL EXPERT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA RENAL CRISIS; SKIN DISEASE; STANDARDIZATION; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE;

ADRENERGIC ALPHA-ANTAGONISTS; ALGORITHMS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HEALTH CARE SURVEYS; HUMANS; SCLERODERMA, SYSTEMIC; TREATMENT FAILURE;

EID: 84864095990     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.01.003     Document Type: Article

References (28)

1. Thompson A.E., Pope J.E. Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis. J Rheumatol 2002, 29(9):1867-1873.
2. Hudson M., Fritzler M.J., Baron M. Systemic sclerosis: Establishing diagnostic criteria. Medicine (Baltimore) 2010, 89(3):159-165. Canadian Scleroderma Research Group. (CSRG).
3. Quillinan N.P., Denton C.P. Disease-modifying treatment in systemic sclerosis: Current status. Curr Opin Rheumatol 2009, 21(6):636-641.
4. Leroy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28(7):1573-1576.
5. Farber H.W., Simms R.W., Lafyatis R. Care of patients with scleroderma in the intensive care setting. J Intensive Care Med 2010, 25(5):247-258.
6. Clements P.J., Furst D.E., Wong W.K., Mayes M., White B., Wigley F., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999, 42(6):1194-1203.
7. Leighton C. Drug treatment of scleroderma. Drugs 2001, 61(3):419-427.
8. Pope J.E., Bellamy N., Seibold J.R., Baron M., Ellman M., Carette S., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44(6):1351-1358.
9. Strange G., Nash P. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Int J Rheum Dis 2009, 12(3):192-206.
10. Khanna D., Denton C.P. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010, 24(3):387-400.
11. Avouac J., Kowal-Bielecka O., Landewe R., Chwiesko S., Miniati I., Czirjak L., et al. European league against rheumatism (EULAR) scleroderma trial and research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009, 68(5):629-634.
12. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 2009, 68(5):620-628.
13. Harding S., Khimdas S., Bonner A., Baron M., Pope J.E., Are S. Combination antibiotics for Chlamydia-induced arthritis: Breakthrough to a cure?. Arthritis Rheum 2010, 62(Suppl 10):1203.
14. Pope J.E., Ouimet J.M., Krizova A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006, 55(1):138-145.
15. Furst D.E., Clements P.J., Steen V.D., Medsger T.A., Masi A.T., D'Angelo W.A., et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998, 25(1):84-88.
16. Fries R., Shariat K., von Wilmowsky H., Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005, 112(19):2980-2985.
17. Herrick A.L., van den Hoogen F., Gabrielli A., Tamimi N., Reid C., O'Connell D., et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011, 63(3):775-782.
18. Shenoy P.D., Kumar S., Jha L.K., Choudhary S.K., Singh U., Misra R., et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial. Rheumatol Oxf Engl 2010, 49(12):2420-2428.
19. Walker K.M., Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011, 38(7):1326-1328. Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group, Canadian Scleroderma Research Group.
20. Hudson M., Baron M., Lo E., Weinfeld J., Furst D.E., Khanna D. An international, web-based prospective cohort to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-Methodology and preliminary results. Int J Rheumatol 2010, 2010. pii: 347402.
21. Teixeira L., Mouthon L., Mahr A., Berezné A., Agard C., Mehrenberger M., et al. Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients. Ann Rheum Dis 2008, 67(1):110-116.
22. Penn H., Denton C.P. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008, 20(6):692-696.
23. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41(9):1613-1619.
24. Li D.K., Yang C., Andrade S., Tavares V., Ferber J.R. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011, 343:d5931.
25. Diav-Citrin O., Shechtman S., Halberstadt Y., Finkel-Pekarsky V., Wajnberg R., Arnon J., et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011, 31(4):540-545.
26. Mastrobattista J.M. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997, 21(2):124-134.
27. Hachulla E., Denton C.P. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: An essential component of disease management. Eur Respir Rev 2010, 19:314-320.
28. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354(25):2655-2666.